Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:21:30.340Z.
Calculation as of: 2026-10-06T17:21:30.340Z.
Quote observation: 2026-10-06T17:15:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f
PE RATIO
N/A
Market Cap
$38.61M
PE Ratio
N/A
TTM Avg
328.93
3Y Avg
271.56
5Y Avg
151.89
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.33M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.89M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $37.78M | 21.93 | 36.35 | 61.12 | 61.12 |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | N/A | 328.93 | 271.56 | 151.89 |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 14.70 | 37.22 | 37.36 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.91M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.88
Forward EPS (Est.)
$-2.07
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
